Shots:

• The initiation of a rolling submission follows positive results from a preclinical viral challenge study of mRNA-1273 and the +ve interim analysis of the P-l study of mRNA-1273 in healthy adults (aged 18-55 yrs.) and older adults (aged 56-70 and 71+)- published in the NEJM
• Moderna has become the third maker that initiates the rolling submission to Health Canada for speeding up the approval. Health Canada is already conducting real-time reviews of BioNTech & Pfizer’s COVID-19 vaccine candidates along with AstraZeneca’s candidate
• The rolling reviews speed up the process of approving a vaccine- allowing researchers to submit findings in real-time- without having to wait for studies to conclude
  
    Ref: Moderna | Image: Moderna